Allergies and supplements
Rogan and Buhler open with seasonal allergies in Austin (cedar) and briefly mention using colostrum products consistently to reduce symptoms.
#2469 - Brigham Buhler
Source description
Brigham Buhler is the founder and CEO of Ways2Well, a functional and regenerative care clinic, and owner of ReviveRx Pharmacy.www.ways2well.comwww.reviverx.com Perplexity: Download the app or ask Perplexity anything at https://pplx.ai/rogan. Get a free welcome kit with …
Brigham Buhler is the founder and CEO of Ways2Well, a functional and regenerative care clinic, and owner of ReviveRx Pharmacy.www.ways2well.comwww.reviverx.com Perplexity: Download the app or ask Perplexity anything at https://pplx.ai/rogan. Get a free welcome kit with your first subscription of AG1 at https://drinkag1.com/joerogan Athletic Brewing Co. Non-alcoholic Beer. Fit For All Times. Athletic Brewing Company LLC. Milford, CT and San Diego, CA. Near Beer <0.5% alc/vol. Learn more about your ad choices. Visit podcastchoices.com/adchoices
Key Topics
- Allergies and supplements
- Peptides reclassification efforts
- FDA transparency and access complaints
- Dogma in medicine ("Blind Spot")
- Hormone therapy policy shift
- Testosterone and prostate cancer debate
- Peptides vs GLP-1 weight-loss drugs
- Off-label prescribing and COVID-era parallels
- Big Pharma lobbying and compounding conflict
- Drug-development economics and NIH role
- Regulatory "wild west" and black/gray markets
- Proposed regulatory solution
- Longevity care models and incentives
- Ways2Well model: diagnostics + monitoring
- AI assistant and care scaling
- Genetics and predictive medicine
- Gordon Ryan case example
- Muse stem cells (overview and claims)
- Plasmapheresis for longevity and microplastics
Peptides reclassification efforts
Buhler says the current administration is working to reclassify certain peptides that were previously labeled as dangerous, describing it as a multi-year effort now showing real progress.
FDA transparency and access complaints
He claims he filed 17 FOIA requests to the FDA without receiving responses, contrasting past stonewalling with new meetings and increased engagement under current leadership.
Dogma in medicine ("Blind Spot")
They discuss how medical groupthink and institutional dogma can override emerging science, citing FDA leadership’s stated openness to revisiting entrenched assumptions.
Hormone therapy policy shift
Buhler argues testosterone and broader HRT risks were overstated for decades and says regulators are now moving to reduce fear-based labeling (e.g., black box warnings) around hormones.
Testosterone and prostate cancer debate
He attributes prostate-cancer fears to an early, weak study and emphasizes a receptor-saturation model, asserting later evidence doesn’t support testosterone therapy causing prostate cancer.
Peptides vs GLP-1 weight-loss drugs
They distinguish between disputed peptides and GLP-1 drugs (also peptides), noting GLP-1 popularity, celebrity use, and concerns about side effects and appearance changes.
Off-label prescribing and COVID-era parallels
Conversation frames peptide prescribing within the broader reality of off-label drug use, referencing COVID controversies (ivermectin/hydroxychloroquine) as examples of profit and policy conflict.
Big Pharma lobbying and compounding conflict
Buhler describes intense pharmaceutical lobbying against compounding pharmacies, arguing the narrative of massive losses is misleading relative to pharma market caps and revenues.
Drug-development economics and NIH role
He critiques the high cost of bringing drugs to market and claims many innovations originate from NIH-funded research, later commercialized by pharmaceutical companies.
Regulatory "wild west" and black/gray markets
He argues restrictions pushed peptide/GLP-1 demand toward black/gray markets with no clinician oversight, variable purity/dosing, and poor guidance for safe preparation and use.
Proposed regulatory solution
Buhler advocates restoring a pathway that keeps peptides in regulated compounding with clinician and pharmacist involvement, emphasizing sterility, sourcing controls, and third-party verification.
Longevity care models and incentives
He contrasts traditional insurance-driven “sick care” with cash-pay longevity care, criticizing both ultra-elite concierge pricing and low-quality high-volume telehealth “pill mill” approaches.
Ways2Well model: diagnostics + monitoring
Buhler describes a scalable longevity clinic approach using extensive diagnostics (bloodwork, DEXA, VO2 max), wearables, home devices, and app-based tracking to personalize care.
AI assistant and care scaling
He outlines using large language models and an in-app assistant to help patients understand plans, refills, and records—positioning AI as a tool to scale high-touch care rather than replace people.
Genetics and predictive medicine
They discuss adding genome sequencing to personalized care, using gene predispositions to guide lifestyle and treatment decisions, and highlighting epigenetics as modifiable risk expression.
Gordon Ryan case example
Buhler shares a gene-testing anecdote about athlete Gordon Ryan, citing rare markers tied to tendon/bone traits and vulnerabilities like infection predisposition and gut acidity.
Muse stem cells (overview and claims)
Buhler highlights “Muse” cells as a rare stem-cell subtype with strong stress tolerance, homing/engraftment, and differentiation potential, presenting them as a promising next step in regenerative medicine.
Plasmapheresis for longevity and microplastics
They discuss therapeutic plasma exchange as an “oil change” concept to reduce circulating inflammatory/toxic burdens, including microplastics/endocrine disruptors, alongside other interventions.